Aarti Pharmalabs Ltd - 543748 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
Aarti Pharmalabs' promoter, Mr. Mirik Rajendra Gogri, pledged 27.84 lakh shares, representing 3.08% of the company's total share capital. The shares were pledged in favor of Bajaj Financial Securities Limited and 360 One Distribution Services Limited for personal use by the promoter group.
Apr 04 2026 10:04:00
Aarti Pharmalabs Ltd - 543748 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
Renil Rajendra Gogri, a promoter of Aarti Pharmalabs, created a pledge on 1.51 million shares, which is 3.89% of the total share capital. The pledge was made in favor of Aditya Birla Money Limited, Bajaj Financial Securities Limited, and 360 One Distribution Services Limited on March 25, 2026.
Apr 04 2026 10:04:00
Aarti Pharmalabs Ltd - 543748 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Aarti Pharmalabs' promoter, Mr. Mirik Rajendra Gogri, pledged 27.84 lakh shares, representing 3.08% of the company's total share capital. The shares were pledged in favor of Bajaj Financial Securities Limited and 360 One Distribution Services Limited for personal use by the promoter group.
Apr 04 2026 10:04:00
Aarti Pharmalabs Ltd - 543748 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Renil Rajendra Gogri, a promoter of Aarti Pharmalabs, created a pledge on 1.51 million shares, which is 3.89% of the total share capital. The pledge was made in favor of Aditya Birla Money Limited, Bajaj Financial Securities Limited, and 360 One Distribution Services Limited on March 25, 2026.
Apr 04 2026 10:04:00
Aarti Pharmalabs Ltd - 543748 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Aarti Pharmalabs' Unit-IV in Tarapur successfully completed its US-FDA inspection on March 27, 2026. The company received a 'Form 483' with one procedural observation, for which corrective actions will be submitted to the US FDA within the stipulated period.
Mar 27 2026 18:03:00
Aarti Pharmalabs Ltd - 543748 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aarti Pharmalabs' Unit-IV in Tarapur successfully completed its US-FDA inspection on March 27, 2026. The company received a 'Form 483' with one procedural observation, for which corrective actions will be submitted to the US FDA within the stipulated period.
Mar 27 2026 18:03:00
Aarti Pharmalabs Ltd - 543748 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Aarti Pharmalabs reported a minor chemical leak at its Tarapur plant on March 22, 2026. The incident led to 22 worker hospitalizations for observation, though more than half have been discharged, and normal plant operations resumed within 24 hours.
Mar 24 2026 12:03:00
Read More